In the longest-running trial comparing tamoxifen with the aromatase inhibitor letrozole, results reveal that letrozole continues to prevent breast cancer recurrences and lower the risk of death in postmenopausal women with hormone receptor-positive early breast cancer.
Men with hormone therapy resistant metastatic prostate cancer endure less fatigue when treated with a combination of abiraterone acetate and prednisone, according to results from an international phase 3 clinical trial.
In response to the increasing costs facing cancer patients, a study recently identified areas for improvement in both the cost and quality of cancer care. The new study. Benchmarks for Value in Cancer Care: An Analysis of a Large Commercial Population, was reported by one of the nation’s largest networks of community-based oncologists dedicated to advancing cancer care in America, the US Oncology Network. The study was published in the State of Oncology supplement of the peer-reviewed Journal of Oncology Practice.
Controlling the pain related to bone metastases in patients with prostate cancer can be difficult. Researchers have now discovered a single dose of a bisphosphonate drug is as effective for pain relief as single-dose radiotherapy, the standard treatment for bone metastases, according to a large randomized phase 3 trial presented at the 2011 European Multidisciplinary Cancer Congress.*
Postmenopausal women with breast cancer benefit significantly from using zoledronic acid as an aid to chemotherapy, according to trial results presented at the 2011 European Multidisciplinary Cancer Congress* and published in the New England Journal of Medicine.1 Could this be the key to unlocking the breast cancer recurrence process as well as advancements toward new breast cancer therapy options? Researchers believe so.
Fear, anxiety, and isolation could all play a role in the etiology of breast cancer aggressiveness, especially for minority patients, according to study results presented at the 4th American Association for Cancer Research Conference on The Science of Cancer Health Disparities.
It was announced on September 19, 2011, that two new indications for Prolia® (denosumab) were approved by the U.S. Food and Drug Administration (FDA). One indication allows for building bone mass in women receiving adjuvant aromatase inhibitor therapy for breast cancer and with an increased likelihood of fracture. The other indication is for increasing bone mass in men being treated with androgen deprivation therapy for nonmetastatic prostate cancer and at great risk for fracture. Read More ›
Monroe Township, NJ. September 15, 2011—Green Hill Healthcare Communications, LLC, a privately held medical communications firm, announced today the launch of a ground-breaking first-of-its-kind journal, Personalized Medicine in Oncology (PMO),the official publication of the Global Biomarkers Consortium (GBC) in Oncology (www.globalbiomarkersconsortium.com).
Patients diagnosed with cancer are living longer than ever before as a result of greater awareness, earlier detection, and improvement in therapies. However, living longer also means facing the symptoms of cancer survivorship, which may have a considerable impact on quality of life for many patients. One such symptom is chemotherapy-induced neuropathic pain, a neurotoxic effect of some chemotherapeutic agents. Unfortunately, currently approved pain medications can have unbearable side effects that preclude the use of effective doses.
Breast and cervical cancer cases and deaths are rising in most areas of the world, and this is especially true in developing countries where more women are dying at younger ages, according to a new global analysis by the Institute for Health Metrics and Evaluation (IHME) at the University of Washington. The new study, “Breast and cervical cancer trends for 187 countries between 1980 and 2010: a systematic analysis,” is published in The Lancet.
The analysis shows:
To sign up for our newsletter or print publications, please enter your contact information below.
